文献速递乳房整形与再造显微修复重建

微血管乳房再造中加速康复外科的成本分析

Cost analysis of enhanced recovery after surgery in microvascular breast reconstruction.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2018-03-02

该回顾性队列研究通过多学科协作制定标准化加速康复外科(ERAS)路径,覆盖以腹部为供区的游离皮瓣乳房再造全程,比较ERAS组与历史对照传统康复(TRAS)组的住院费用。共分析200例(ERAS组82例、TRAS组118例),调整单侧与双侧手术(p=0.04)及术后输血需求(p=0.03)后,ERAS组调整后平均费用较TRAS组少4576美元(38688美元 vs 43264美元)。

要点

  • ERAS路径覆盖游离皮瓣乳房再造全程,由多学科协作制定。
  • 调整混杂变量后,ERAS组平均费用较TRAS组少4576美元。
  • 两组单侧与双侧手术比例(p=0.04)及术后输血需求(p=0.03)差异有统计学意义。

核心结论

  • 实施ERAS路径与历史对照相比费用显著降低。
  • ERAS路径可在提高医疗质量的同时降低自体乳房再造相关费用,增强医疗责任。

研究设计与样本

  • 回顾性队列研究,通过多学科协作制定标准化ERAS路径,覆盖以腹部为供区的游离皮瓣乳房再造各阶段。
  • 共分析200例,ERAS组82例,TRAS历史对照组118例,手术时间在2010年9月至2014年9月之间。
  • 采用广义线性模型比较两组预测费用,并调整单侧与双侧手术及术后输血需求等显著变量。

主要发现

  • 单侧与双侧手术在两组间差异有统计学意义(p=0.04)。
  • 术后输血需求在两组间差异有统计学意义(p=0.03)。
  • ERAS组调整后平均费用为38688美元,TRAS组为43264美元,ERAS组少4576美元。

临床怎么用

  • 作者认为ERAS路径可提高医疗责任,在改善医疗质量的同时降低自体乳房再造相关费用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enhanced recovery after surgery (ERAS) pathways have been shown in multiple surgical specialties to decrease hospital length of stay (LOS) after surgery. ERAS in breast reconstruction has been found to decrease hospital LOS and inpatient opioid use. ERAS protocols can facilitate a patient's recovery and can potentially increase the quality of care while decreasing costs. METHODS: A standardized ERAS pathway was developed through multidisciplinary collaboration. It addressed all phases of surgical care for patients undergoing free-flap breast reconstruction utilizing an abdominal donor site. In this retrospective cohort study, clinical variables associated with hospitalization costs for patients who underwent free-flap breast reconstruction with the ERAS pathway were compared with those of historical controls, termed traditional recovery after surgery (TRAS). All patients included in the study underwent surgery between September 2010 and September 2014. Predicted costs of the study groups were compared using generalized linear modeling. RESULTS: A total of 200 patients were analyzed: 82 in the ERAS cohort and 118 in the TRAS cohort. Clinical variables that were identified to potentially affect costs were found to have a statistically significant difference between groups and included unilateral versus bilateral procedures (p = 0.04) and the need for postoperative blood transfusion (p = 0.03). The cost regression analysis on the two cohorts was adjusted for these significant variables. Adjusted mean costs of patients with ERAS were found to be $4,576 lesser than those of the TRAS control group ($38,688 versus $43,264). CONCLUSIONS: Implementation of the ERAS pathway was associated with significantly decreased costs when compared to historical controls. There has been a healthcare focus toward prudent resource allocation, which dictates the need for plastic surgeons to recognize economic evaluation of clinical practice. The ERAS pathway can increase healthcare accountability by improving quality of care while simultaneously decreasing the costs associated with autologous breast reconstruction.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Oh C, Moriarty J, Borah BJ, et al. Cost analysis of enhanced recovery after surgery in microvascular breast reconstruction. J Plast Reconstr Aesthet Surg. 2018. PMID: 29606583. doi:10.1016/j.bjps.2018.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。